CORBEIL-ESSONNES Cedex, France Clinical Trials

A listing of CORBEIL-ESSONNES Cedex, France clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 5 clinical trials
First Line Metastatic Pancreatic Cancer : 5FU/LV+Nal-IRI Gemcitabine+Nab-paclitaxel or a Sequential Regimen of 2 Months 5FU/LV+Nal-IRI

In Europe, pancreatic cancer (PC) is the 7th most common cancer and the 5th leading cause of cancer death in Europe. Each year, the number of deaths due to prostate cancer is almost as high as the number of new cases diagnosed reflecting the poor prognosis associated with this disease. …

measurable disease
liver metastasis
serum pregnancy test
gemcitabine
paclitaxel
CH Sud Francilien
 (0.0 away) Contact site
  • 10 views
  • 22 Jan, 2021
  • +47 other locations
Investigating Otilimab in Patients With Severe Pulmonary COVID-19 Related Disease

OSCAR (Otilimab in Severe COVID-19 Related Disease) is a multi-center, double-blind, randomized, placebo-controlled trial to assess the efficacy and safety of otilimab for the treatment of severe pulmonary COVID-19 related disease. The study is being conducted in 2 parts (Part 1 and Part 2). Otilimab is a human monoclonal anti-granulocyte …

glucose
pneumonia
mechanical ventilation
x-rays
hypoxia
GSK Investigational Site
 (9.5 away) Contact site
  • 99 views
  • 01 May, 2021
  • +111 other locations
Aflibercept +/- LV5FU2 in First Line of Non-resectalbe Metastatic Colorectal Cancers

This is what the FFCD 11-01 - PRODIGE 25 trial proposes to study, as a preliminary for strategic studies evaluating the usefulness of including targeted therapeutics from the first line with aflibercept +/- LV5FU2.

neutrophil count
adenocarcinoma of colon
adenocarcinoma
metastasis
anticoagulants
Centre hospitalier Sud Francilien
 (0.0 away) Contact site
  • 22 views
  • 24 Jan, 2021
  • +89 other locations
Evaluation of Risk-Adapted and MRD-Driven Strategy for Untreated Fit Patients With Intermediate Risk Chronic Lymphocytic Leukemia

The aim of this study is to test the potential benefit of an innovative combination of targeted therapy over the standard the immunochemotherapy (FCR). The interest in this study resides in an MRD driven discontinuation of the novel agents, and a fixed maximum duration of these agents. This design allows …

Centre Hospitalier Sud Francilien
 (0.0 away) Contact site
  • 0 views
  • 24 Jan, 2021
  • +52 other locations
Safety and Efficacy of Ponatinib Followed by Imatinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase

The investigators hypothesize that, in newly diagnosed de novo chronic phase CML patients, an induction treatment with ponatinib for 6 months should increase the rate of patients reaching a stable MR4.5 allowing cessation of imatinib treatment. The investigators proposal is to conduct a multicenter, Phase II trial to evaluate the …

lipase
philadelphia chromosome
hydroxyurea
basophils
interferon
Centre Hospitalier Sud Francilien
 (1.9 away) Contact site
  • 0 views
  • 14 May, 2021
  • +34 other locations